Enhanced surveillance for meningococcal disease in Queensland in 1999 by Ward, J. et al.
Enhanced surveillance for meningococcal
disease in Queensland in 1999
Justine Ward,
1
Jeffrey N Hanna,
2
John R Bates,
3
Linda A Selvey
4
Abstract
Enhanced surveillance of invasive meningococcal disease commenced in Queensland in 1999. There were 93 cases,
an incidence of 2.8/100,000 population. Most (87%) cases were laboratory confirmed, but 12 per cent were probable
cases without laboratory confirmation. The highest age-specific attack rates were in the under 1, 1 to 4 and 15 to 24
year age groups. Most of the serologically characterised isolates were group B (70%), followed by group C (24%).
There were 12 deaths, resulting in a case fatality rate of 13 per cent. Those who died were more likely to have group
C than group B disease (OR 5.04, CI 1.05-25.14). Only 14 per cent of cases that saw a general practitioner (GP) prior
to hospitalisation received parenteral antibiotics, 23 per cent of the 35 cases referred to hospital by a GP received
pre-hospital parenteral antibiotics and 33 per cent of cases were notified to health authorities within 24 hours of
hospital admission. Thirty per cent were notified two or more days after hospitalisation, delaying the start of public
health action. Enhanced surveillance has demonstrated a need to promote the use of pre-hospital parenteral
antibiotics by GPs and a need to encourage more timely reporting of cases to health authorities. Commun Dis Intell
2000;24:332-336.
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Introduction
Before 1999, only laboratory-confirmed cases of invasive
meningococcal disease (IMD)* were routinely notified in
Queensland. Because the probable clinical cases (with no
laboratory confirmation) were not notified, an under-
ascertainment of the true incidence of IMD resulted.
Furthermore, important information (such as the indigenous
status, the clinical and public health management, and the
clinical outcome of each patient) was not routinely collected.
From the beginning of 1999, public health physicians
implemented ‘enhanced’ surveillance of IMD in Queens-
land, which not only included probable clinical cases, but
also extra details on each case. In this report we describe
(i) the epidemiology of IMD in Queensland in 1999, (ii) the
relevant details of the clinical and public health management
of the cases, and (iii) the completeness of the information
collected through the enhanced surveillance.
Methods
A standard surveillance report form for IMD, based upon that
used in New Zealand1 was developed for use by Public
Health Units (PHUs) throughout Queensland. A case of IMD
was defined as:-
• Confirmed, if there was a clinically compatible illness and
at least one of: (i) isolation of Neisseria meningitidis from
a normally sterile site, or (ii) detection of gram-negative
diplococci in a specimen from a normally sterile site, or
(iii) a positive meningococcal antigen test on cerebro-
spinal fluid (CSF) or (iv) detection of meningococcal DNA
in a specimen from a normally sterile site.
• Probable, if there was a clinically compatible illness and
at least one of: (i) a petechial or purpuric rash, or (ii)
isolation of N. meningitidis from a throat swab,2 (iii) an
epidemiological link to a confirmed case.
’Disease onset‘ for the calculation of timeliness of
hospitalisation refers to this episode of illness, and includes
the spectrum of disease from those who were mildly unwell
initially to those with classic meningococcal disease.
Where possible the PHUs obtained the information detailed
on the report form from the patient, the immediate contacts
or the clinicians. Data from completed forms forwarded to
the Communicable Disease Unit (CDU), Queensland
Health, Brisbane, were entered on a computerised
database.
Pathology laboratories throughout Queensland refer
meningococcal isolates to Queensland Health Scientific
Services (QHSS), Brisbane, for confirmation of the
serogrouping and for further phenotypic characterisation.
These laboratory data were also sent to the CDU for entry on
its database.
The database was analysed using Epi Info version 6.04b
and Windows Excel 97. Data from the 1996 national census
were used to calculate incidence rates.
Results
Epidemiology and clusters
In all there were 93 cases of IMD in Queensland in 1999, an
incidence of 2.8/100,000 population. The median age was
16.3 years (range 0.2 to 84.4 years) and the male:female
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ratio was 1:1.1. The highest number of cases occurred in the
under 1 and 1 to 4 years age groups (11.8% and 22.6% of
cases respectively). There was a secondary peak in the 15
to 19 years age group that extended into the 20 to 24 years
age group (Figure 1).
A typical winter peak was exhibited in 1999 with 48.4 per
cent of cases occurring between May and August. There
was no clustering by town or suburb in 1999. Indigenous
status was recorded in 81 (87%) of cases. Six of these cases
(7.4%) were indigenous, all children under 15 years of age
(four cases were under 5 years).
There were two recognised clusters in 1999. The first in May
1999 was of serogroup B disease among three people. Two
had been passengers in the same train on the same date
and the third case was a contact of one of the travellers.
There was no known direct contact between the two train
passengers but one was sitting behind the other for
approximately 24 hours. The first two were co-primary
cases; the third became ill 11 days after the primary cases.
Analysis of the DNA of isolates using pulsed field gel
electrophoresis (PFGE) confirmed that these cases were
linked.
The second cluster in July 1999 was two cases of serogroup
C disease, also confirmed by PFGE. The second case had
illness onset 3 days after the first case and was a contact of
a contact of the first case.
Laboratory diagnosis
Of the 93 cases, 81 (87%) were confirmed, 11 (12%) were
probable and one could not be categorised due to missing
data. Of the confirmed cases, 67 were culture-positive; 4
were confirmed by PCR alone, 6 by detection of
gram-negative diplococci in blood or CSF alone and 4 by a
combination of PCR, antigen detection or organism
detection. All 11 probable cases were diagnosed by a
clinically compatible illness in association with a rash.
All 67 isolates were serogrouped; 47 (70%) were group B,
16 (24%) were group C and there were 2 each of group Y
and W135. Of the 11 isolates from fatal cases, 6 were group
C and 5 were group B.
Forty (63.5%) of the 63 group B and C isolates could be
further serotyped. No strain predominated among the group
C isolates. The most commonly isolated strains among the
group B isolates were 4:P1.4 (7) (n=5) and 15:P1.7 (n=5).
Serogroup B infections outnumbered serogroup C infections
in all age groups, with the ratio being highest in the under
one-year age group (Figure 2).
Clinical features, clinical management and outcomes
Twenty-one of the 93 cases (22.6%) were recorded as
having both meningitis and septicaemia, 19 cases (20.4%)
presented with septicaemia alone, 20 (21.5%) with men-
ingitis alone and 2 (2.2%) with septic arthritis alone. A
petechial or purpuric rash occurred in 57 (61%) of present-
ations. All 12 cases that died presented with septicaemia
and 5 of these also had a meningitic component.
The 12 deaths from IMD represented a case fatality of 13 per
cent, with the highest proportion of case fatalities in the 20 to
29 years (29%) and 1 to 4 years (19%) age groups. The
median age of those dying was 19 years, compared with
14.9 years for those surviving.
Those with serogroup C disease were more likely to die than
those with serogroup B disease (OR 5.04, 95% CI
1.05-25.14, p = 0.02) and those with a rash were more likely
to die than those without (OR 5.96, 95% CI 0.7-133.2, p =
0.09). Those who saw a general practitioner (GP) prior to
hospitalisation were less likely to die than those who did not
(OR 0.24, 95% CI 0.05 -1.01, p = 0.05).
Information on which cases saw a GP prior to hospitalisation
was available in 89 cases; 56 (63%) saw a doctor, of these 8
(14%) were recorded as having received parenteral
antibiotics. Information on which cases were referred to
hospital by a GP was available in 86 cases; of these, 35
(41%) were referred to a hospital. If only those cases
referred to hospital by the GP (ie. those in whom the GP
probably suspected meningococcal disease) are used as
the denominator, the percentage of cases receiving
pre-hospital parenteral antibiotics increased to 23 per cent
(8/35).
Meningococci were isolated from 2 (25%) of the 8 cases
who received pre-hospital parenteral antibiotics (p = 0.05)
and from 55 (67%) of the 82 cases who did not.
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Figure 1. Number of meningococcal cases,
Queensland, 1999, by age group and sex
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Figure 2. Number of meningococcal cases,
Queensland, 1999, by age group and
serogroup
Of the 56 cases who saw a GP prior to hospital admission,
36 (64%) were admitted within 24 hours of being seen
(Table 1) while 18 (32%) took one day or more to be
hospitalised. Of the 12 who died, 4 had been seen by a GP
prior to hospitalisation, and of these 3 were referred to
hospital; one had been treated pre-admission with
parenteral antibiotics.
Fifty-eight (62%) of the cases were hospitalised in less than
48 hours from disease onset (Table 1). The median number
of days between disease onset and hospitalisation was one
day for both those who survived and those who died.
Eleven of 78 cases (14.1%) had a throat swab taken at the
time of the first dose of antibiotics and 67 of 85 cases
(78.8%) had blood cultures taken. Eighteen cases had
neither blood cultures nor throat swabs taken before
antibiotic administration.
Public health management
Information on time taken for notification was available in 83
(89%) of cases; in 25 (30%) of these it took two or more days
for the local PHU to be notified of the hospitalisation
(Table 1). In all but one of 40 cases for whom there was
enough information to calculate response time this was one
hour or less.
In most episodes, household contacts were the main type of
contact (n = 77), followed by contact with oral secretions
(n = 34), other close contacts (n = 26), institutional (n = 9)
and childcare (n = 5) contacts. On average, 11.7 contacts
per case were eligible for chemoprophylaxis; none was
offered vaccine in 1999.
Table 2 lists the percentages of missing data by section
(excluding the section on laboratory details for which data
are obtained from reference laboratories). In general, fields
that related to time (eg. time of initial response, time of
onset, time seen by GP, time hospitalised) had the highest
percentage of missing data. Indigenous status is an
important field for which there were 12 entries missing.
Discussion
At 2.8/100,000, the incidence of IMD in Queensland in 1999
was similar to that in Australia in 1998 (2.4/100,000).3 This
contrasts with the considerably greater incidence in England
and Wales (5/100,000 in 1998), and New Zealand
(13.9/100,000 in 1999).4 The latter extremely high incidence
reflects the sustained epidemic of serosubtype B:4:P1.4
disease in New Zealand.4 This strain is also present in
Queensland, although the numbers are small and have
remained similar since 1996.5
The incidence of IMD by age group and season was typical
of that generally described in developed countries. Most
cases were sporadic, with only two confirmed clusters. At
7.4 per cent, the proportion of meningococcal disease
among those identified as indigenous was high compared
with the proportion of indigenous people in the general
population (2.8%). Monitoring of IMD trends in the
indigenous population needs to continue.
The diagnosis of meningococcal disease was confirmed in
most cases by isolation of the organism from blood or CSF.
The proportion of positive cultures was reduced in those
who had received pre-hospital antibiotics. With the
continued emphasis on the importance of pre-hospital
antibiotics, and the increasing reluctance of clinicians to
undertake lumbar puncture, non-culture diagnostic tests (in
particular PCR) will increasingly be required to confirm a
diagnosis of IMD. In addition to confirming the presence of
meningococcal DNA, PCR testing has the capability to
determine serogroups, serotypes and serosubtypes from
clinical specimens.6
The hallmark of meningococcal septicaemia is a haem-
orrhagic rash that does not blanch under pressure.7
Modelled on initiatives in England and New Zealand, for the
first time in 1999 all GPs and emergency department
physicians in Queensland were sent pictorial information
depicting the typical rash of meningococcal disease. A rash
was present in 57(66%) of cases, and all 12 patients dying
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Table 1. Days from general practitioner visit and meningococcal disease onset to hospitalisation, and from
hospitalisation to notification, Queensland 1999
Time interval
Days
<1 1 2 3 4 5 6 7 NR*
Total
cases
From GP visit to
hospital admission
36 12 5 0 1 0 0 0 2 56
From disease onset to
hospital admission
23 35 14 5 2 2 2 2 8 93
From hospitalisation to
notification (probable)
31(3) 27(5) 15(1) 5 1 3(1) 0 1 10(1) 93(11)
* Not recorded
Table 2. Mean percentages of data missing from
surveillance report forms, by section
Section
Mean
missing data
(%)
Range
(%)
Notifier details 21.4 2.2 - 45.2
Patient details 13.1 0 - 72.0
Clinical presentation 15.1 7.5 - 23.7
Status (confirmed/probable) 9.7
Clinical course 13.1 0 - 46.2
Case management 13.2 0 - 16.1
Risk factors 10.4 0 - 50.0
Outbreak details (Yes/No) 11.8
had septicaemia. GPs were urged to administer parenteral
penicillin to anyone displaying the symptoms and signs of
meningococcal septicaemia. Despite this, only 23 per cent
of the cases referred to a hospital by a GP received
pre-hospital parenteral antibiotics. The questionnaire did not
record whether the GP suspected IMD, a question now
included in the latest version.
Recent experience in New Zealand has documented a
significantly lower case fatality in patients given antibiotics
prior to hospitalisation.4 Numbers reported here were too
small to show this. Although other determinants of disease
outcome, such as the severity at initial presentation, could
influence the association between pre-hospital antibiotic
use and case fatality, the early administration of antibiotics is
generally considered the most important means to prevent
IMD deaths. Further initiatives are needed to get GPs to
administer parenteral penicillin to possible IMD cases, and
monitoring of the proportion given pre-hospital antibiotics
should continue.
Seventy per cent of isolates in Queensland in 1999 were
serogroup B, not dissimilar to the proportion reported
nationally in 1998 and 1999 (63%).3,8 Queensland differed
from Victoria and New South Wales in 1999 in that group C
disease did not predominate in the 15-44 age group.8
Although the small number of cases meant that the
confidence intervals were wide, the group C case fatality
rate (CFR) was significantly higher than that for group B
disease. National data for 1999 were similar (CFR in group
C disease was 14.9 per cent compared with 6.4 per cent in
serogroup B disease).8 As an effective vaccine against this
serogroup is available, these deaths are potentially
preventable and decisions about whether or not to introduce
routine vaccination need to be reviewed continually.9
Because the risk of secondary cases is much greater in the
days immediately following the onset of the index cases than
later on, immediate notification of suspect cases of IMD to
PHUs is crucial so that contacts can be identified,
counselled and offered chemoprophylaxis if indicated.10
That only 33 per cent were notified within 24 hours of
hospital admission, and 30 per cent notified two or more
days after hospitalisation, is thus of considerable concern.
Late reporting may indicate some clinicians await laboratory
confirmation before notification. Further efforts to get
clinicians to notify cases upon clinical suspicion are
required.
Public health physicians agreed unanimously that IMD be
the first disease for enhanced surveillance in Queensland.
Therefore the amount of missing information is both
surprising and disappointing. Some fields, such as
‘indigenous status’ and ‘outcome’ were considered
important enough to justify enhanced surveillance. High
proportions of missing data in some fields (Table 2) may
reflect a need to clarify the form, but PHUs should attempt to
ensure that the enhanced surveillance report forms are
completed with reliable detail. Further monitoring of the
completeness of information collected by PHUs is
necessary.
In conclusion, the first year of enhanced surveillance in
Queensland has already demonstrated the need to improve
(i) GP awareness of the diagnosis of IMD, and the
effectiveness of parenteral administration of antibiotics prior
to the urgent referral to hospital, (ii) the timeliness of
notification of IMD by clinicians, and (iii) the completeness of
the information collected by PHUs on each case of IMD.
Extra costs beyond those normally involved in collecting
data for case management were minimal and mainly related
to data entry and analysis.
Continued enhanced surveillance will enable detection of
trends. However these may need to be interpreted with
caution, given that increasing identification of cases by
non-culture based methods means that increasing numbers
of milder cases are likely to be uncovered.8 Data pooled over
several years will allow more meaningful analysis of risk
factors and management practices, as would adoption of
enhanced surveillance nationally.
* Abbreviations:
CDU, Communicable Disease Unit; CFR, case fatality rate;
CSF, cerebrospinal fluid; GP, general practitioner; IMD,
invasive meningococcal disease; PCR, polymerase chain
reaction; PHU, Public Health Unit; PFGE, pulsed field gel
electrophoresis; QHSS, Queensland Health Scientific
Services.
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